Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus – Nasdaq
Bloomberg |
Kymriah, First CAR–T Therapy Approved: 4 Pharma Stocks in Focus
Nasdaq Kymriah, formerly CTL019, is the first chimeric antigen receptor T cell (CAR-T) therapy approved. A novel immunocellular therapy and one-time treatment, Kymriah uses patient’s T cells to fight cancer. While the long-term impact of the treatment is yet … FDA Vows Modernization to Keep Up With Biotech AdvancesBloomberg |
|
Merck’s immunotherapy, chemo mix shows extended lung cancer gains
Reuters MADRID (Reuters) – Giving Merck & Co’s immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. |
Reuters |
Roche blood test could help ‘personalize’ cancer immunotherapy
Reuters Evidence shows that tumors with more mutations are more likely to respond to immunotherapy, Roche said, adding that it hoped its and Foundation’s new test would improve measuring TMB where invasive tumor biopsies that can be tough to evaluate are … |
WHTC |
Roche blood test could help ‘personalize’ cancer immunotherapy
WHTC Evidence shows that tumors with more mutations are more likely to respond to immunotherapy, Roche said, adding that it hopes the new test will improve measuring TMB, particularly when invasive biopsies are not feasible. There are no such blood tests on … Roche hopes blood test will predict immunotherapy efficacypharmaphorum Roche blood test can accurately predict immunotherapy efficacyPharmaTimes |
|
FDA Suspends UCART123 Trials After Patient Death
Immuno-Oncology News The U.S. Food and Drug Administration (FDA) has suspended two Phase 1 trials assessing Cellectis’ CAR T-cell therapy UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) after the first patient died. |
|
FDA Suspends UCART123 Trials After Patient Death
Immuno-Oncology News The U.S. Food and Drug Administration (FDA) has suspended two Phase 1 trials assessing Cellectis’ CAR T-cell therapy UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) after the first patient died. |
OncLive |
Dr. Argiles Discusses the Role of Immunotherapy in CRC
OncLive Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer (CRC). There is an important role for immunotherapy in the hyper-mutant population of … |
The Straits Times |
Comic-stripping science of its mysteries
The Straits Times “They feel that the future will be greatly changed by synthetic biology, and Hollywood has given it a bad name by presenting a dystopia in movies where mad scientists create horrible monsters by manipulating DNA,” said Mr Fong. He said the scientists … |